Diroximel fumarate – a new twist for MS agent best seller

IF 1.3 Q4 NEUROSCIENCES Progress in Neurology and Psychiatry Pub Date : 2022-07-01 DOI:10.1002/pnp.752
T. Gaber
{"title":"Diroximel fumarate – a new twist for MS agent best seller","authors":"T. Gaber","doi":"10.1002/pnp.752","DOIUrl":null,"url":null,"abstract":"Fast track appraisal (FTA) was adopted by NICE in 2017. This faster and more simplified process is mainly used for novel pharmaceutical agents that are considered bioequivalent to an already recommended drug with added advantages or reduced costs. In June 2022 NICE used FTA to recommend diroximel fumarate (Vumerity) for the management of relapsing remitting multiple sclerosis (RRMS). This short article explores the potential role the drug may play within the pantheon of disease modifying treatment for RRMS.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neurology and Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pnp.752","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Fast track appraisal (FTA) was adopted by NICE in 2017. This faster and more simplified process is mainly used for novel pharmaceutical agents that are considered bioequivalent to an already recommended drug with added advantages or reduced costs. In June 2022 NICE used FTA to recommend diroximel fumarate (Vumerity) for the management of relapsing remitting multiple sclerosis (RRMS). This short article explores the potential role the drug may play within the pantheon of disease modifying treatment for RRMS.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
富马酸地洛昔梅尔- MS代理的新转变畅销书
NICE于2017年采用了快速通道评估(FTA)。这种更快、更简化的过程主要用于新型药物,这些药物被认为与已经推荐的药物具有生物等效性,具有额外的优势或降低了成本。2022年6月,NICE使用FTA推荐富马酸二肟(Vumerity)用于复发缓解型多发性硬化症(RRMS)的治疗。这篇短文探讨了该药物在RRMS疾病改良治疗中可能发挥的潜在作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.70
自引率
8.30%
发文量
44
期刊介绍: Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.
期刊最新文献
Transforming care planning: linking risk assessment and risk management Othello syndrome and dopamine dysregulation syndrome Amyloid angiopathy‐related inflammation: a case report Joint primary and secondary care study of lithium prescribing and monitoring Royal College of Psychiatrists International Congress 2023
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1